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the Malaria Drug Accelerator Consortium20Highlights
Novel antimalarial therapies are required
to combat drug-resistant Plasmodium
falciparum (Pf) and help with malaria
elimination.
To address the need for antimalarial
drugs, Malaria Drug Accelerator (MalDA),
a public–private partnership, was formed
in 2012. Today, it is a consortium of
15 academic and industrial laboratories
whose collective expertise and resourcesThe Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific
laboratories. The aim ofMalDA is to improve and accelerate the early antimalarial
drug discovery process by identifying new, essential, druggable targets. In
addition, it seeks to produce early lead inhibitors that may be advanced into drug
candidates suitable for preclinical development and subsequent clinical testing
in humans. By sharing resources, including expertise, knowledge, materials, and
reagents, the consortium strives to eliminate the structural barriers often
encountered in the drug discovery process. Here we discuss the mission of the
consortium and its scientific achievements, including the identification of new
chemically and biologically validated targets, as well as future scientific directions.have been brought together to accelerate
malaria drug development.
Over the last decade, MalDA has devel-
oped a collaborative pipeline, applying
multiple biomedical, biotechnological,
and cheminformatic approaches to the
identification of novel drug targets.
Due to the significant progress in identify-
ing novel validated targets, advanced
target-baseddrug discovery is underway.
Chemists are performing hit-to-lead com-
pound optimization on inhibitors of many
chemically validated targets, including Pf
phenylalanyl-tRNA synthetase (PheRS),
Pf acetyl-CoA synthetase (AcAS), and Pf
Niemann–Pick type C1-related protein
(NCR1).
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For centuries, malaria has been a threat to global health and in 2019 over 400 000 people,
mostly children under the age of five, died from malaria [1]. Although the use of insecticide-
treated bed nets and artemisinin-based combination therapies have reduced the burden of
malaria, the spread of resistance to first-line antimalarials, the loss of insecticide efficacy, and a
rising number of cases highlight the need for new medicines, treatment modalities, and control
measures.
Fortunately, interest in antimalarial drug development has increased over the past decade
[1]. As a result, there are now at least 13 antimalarial agents in clinical development with
the Medicines for Malaria Venture (MMV) and partnersi. However, there will be attrition:
some of these drug candidates will drop out during preclinical development due to, for
example, lack of in vivo efficacy, formulation, unacceptable levels of parasite resistance, or
safety issues. In addition, some compounds target only the Plasmodium blood stage,
which causes malaria symptoms (Box 1). Therefore, there remains an important need for
new antimalarial medicines, especially those that, in addition to treating Plasmodium
falciparum malaria, also prevent transmission (to the human or mosquito vector) or provide
a radical cure in the case of infection with Plasmodium vivax or Plasmodium ovale malaria,
or work prophylactically.
Recognizing that private investment in malaria research is likely to be limited, the Malaria
Drug Accelerator (MalDA) was formed in 2012. Currently, MalDA is a consortium of
15 scientific laboratories (Figure 1) whose contributions are funded by the Bill and Melinda
Gates Foundation (BMGF). The goal of MalDA is to accelerate the development of
new therapies for malaria by investing in new target discovery, screening, and hit-to-lead de-
velopment. The objective of the consortium is to use resources collaboratively by sharingTrends in Parasitology, June 2021, Vol. 37, No. 6 https://doi.org/10.1016/j.pt.2021.01.009 493
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Box 1. Plasmodium Life Cycle and Points for Intervention
Malaria is a general term for a febrile infection caused by Plasmodium parasites, andmay be caused by at least five different
species of the parasite, each of which may show differential sensitivity to drugs and which have different drug-resistance
profiles. P. falciparum is the deadliest species, whereas P. vivax accounts for malaria relapse, making it a major challenge
to malaria eradication. The Plasmodium parasite life cycle involves the Anopheles mosquito as vector and a vertebrate
secondary host. In the human host, the parasite undergoes exoerythrocytic (liver-stage) and intraerythrocytic asexual
development. Activation of dormant P. vivax hypnozoites in the liver causes malaria relapse. The intraerythrocytic asexual
division of Plasmodium parasites causes the clinical symptoms of malaria. During each intraerythrocytic asexual cycle, a
subpopulation of parasites commits to sexual development into gametocytes. Mature gametocytes are ready to be taken
up by mosquitoes; hence the gametocyte stage is crucial for malaria transmission (Figure I).
While many antimalarial compounds target the pathogenic asexual blood stages, ideally, new antimalarials should also target
other stages. Target candidate profiles (TCPs) were proposed in 2013 as strategic tools to guide malaria drug discovery.
Currently, there are five TCPs [73] (Figure I):
TCP1: Molecules that clear asexual blood-stage parasitemia – blood-stage treatment.
TCP3: Molecules with activity against hypnozoites – hypnozoite antirelapse treatment.
TCP4: Molecules with activity against hepatic schizonts – liver prophylaxis.
TCP5: Molecules that block transmission (targeting parasite gametocytes) – gametocyte transmission blocking.















Figure I. Plasmodium Life Cycle and Points for Intervention. Abbreviation: TCP, target candidate profile.
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Glossary
Allele fraction: next-generation short-
read sequencing returns the number of
reads at a particular locus. The allele
fraction represents the fraction of reads
that are different from the reference
genome.
Cellular thermal-shift assay
(CETSA): a label-free proteomics-
based method that allows the
quantification of a compound and its
target interaction in intact cells.
Copy number variation (CNV): the
number of copies of a particular gene
varies from one individual parasite to the
next.
EC50: the concentration of a drug that
gives a half-maximal response.
gRNA: a short guide (g)RNA that directs
the Cas9 nuclease to bind and cut the
target site in the genome.
In vitro evolution and whole-
genome analysis (IVIEWGA): a
method used extensively with
P. falciparum parasites for target
discovery and chemical validation.
Irresistible compound: a compound
that, using in vitro evolution methods,
failed to yield resistant parasites.
Metabolic fingerprints (MetaPrints):
a metabolomics approach to broadly
characterize metabolic phenotypes and
identify differences in specific parasite
metabolites after a compound
challenge.
Minimum inoculum for resistance
(MIR): the lower the MIR is, the higher
the probability that in vitro drug
resistance occurs.
Mode of action (MOA): how a given
drug exerts activity in a cell.
Multidrug-resistance genes
(MDRs): genes contributing to
resistance mechanisms that render
parasites resistant to multiple
antimalarials independently of their
mode of action.
Single-nucleotide variant (SNV): a
DNA sequence variation that occurs
when a single nucleotide in the genome
sequence is altered.
Structure–activity relationship
(SAR): a relationship that can be used
to predict compound biological activities
from their molecular structures.
Target-less compound: a compound
that, using in vitro evolution methods,
yielded only general resistance
mechanisms.
Trends in Parasitology
Figure 1. Overview of MalDA (Malaria Drug Accelerator). MalDA is a consortium of 15 scientific laboratories (B), working
in the earliest stages of drug discovery. By collaborating and sharing compounds and resources,MalDA can achievemilestones
quickly and efficiently (A). Abbreviations: BMGF, Bill and Melinda Gates Foundation; Calibr, California Institute for Biomedical
Research; CUIMC, Columbia University Irving Medical Center; DDU, Drug discovery unit – University of Dundee; GHDDI,
Global Health Drug Discovery Institute; GSK, GlaxoSmithKline; Harvard Chan, Harvard T.H. Chan School of Public Health;
HTS, High-throughput screening; IVIEWGA, in vitro evolution and whole-genome analysis; MIT, Massachusetts Institute of
Technology; MMV, Medicines for Malaria Venture; Penn State, The Pennsylvania State University; SDDC, Structure-guided
Drug Discovery Coalition; TropIQ, TropIQ Health Sciences; UCSD, University of California San Diego; UCT, University of
Cape Town; WGS, Whole-genome sequencing; WUSTL, Washington University in St Louis.
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OPEN ACCESSreagents, materials, and expertise, thus preventing 'siloing' of projects or knowledge and im-
proving efficiency (Figure 2).
History of Antimalarial Drug Discovery
To understand MalDA, it is important to know the history of antimalarial drug discovery work over
the past century. Initially, natural products, such as quinine and artemisinin (see the review in [2]),
were used in malaria treatment. Further, semisynthetic artemisinin derivatives were developed to
improve the poor biopharmaceutical properties of artemisinin. However, resistance to this drug
emerged as a result of noncompliance with the 3-day regimen, artemisinin's short half-life, and
parasite recrudescence. This, in turn, limits artemisinin’s therapeutic effects [3]. In response to
this issue, fully synthetic antimalarials, such as OZ277 and OZ439 were developed with improved
pharmacokinetics aiming to overcome artemisinin resistance. These are often based on chemicalTrends in Parasitology, June 2021, Vol. 37, No. 6 495
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Figure 2. Overview of MalDA (Malaria Drug Accelerator) Pipeline for the Discovery of Novel Antimalarials.
Phenotypic drug discovery includes screening compound libraries against blood- and liver-stage Plasmodium parasites (A).
The first steps to identify the target of an active hit compound utilize in vitro evolution and whole-genome analysis (IVIEWGA),
metabolomics, chemoproteomics, and chemoinformatics approaches, followed by target validation via genetic and chemical
approaches (B). Genetic validation uses clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) to
reconstitute the resistant alleles found in IVIEWGA experiments. In conditional knockdown (KD) experiments, parasites are
subjected to compound challenges to probe for dose–response changes (chemical validation and vulnerability assessment)
and confirm compound hypersensitivity through diminished target expression (B). Validated targets can be rescreened for
additional specific inhibitors using, for example, DNA-encoded libraries or target-specific libraries (C). Active compounds
from phenotypic screening assays can also be directed to hit-to-lead development to be optimized for enhanced
pharmaceutical properties. The resulting lead compounds are further examined in the in vitro assays against different malaria
parasite developmental cycles and in vivo efficacy and pharmacokinetic/pharmacodynamics (PK/PD) studies in Plasmodium
falciparum severe combined immunodeficiency (SCID) or NSG mouse models (D).
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OPEN ACCESSscaffolds of older natural products. For example, OZ277 and OZ439 incorporated the endoper-
oxide bridge of artemisinin [4,5]; OZ277 is now marketed as Synriam (in combination with
piperaquine) [6], and OZ439 is in clinical trials [7].
Over the past 15 years, antimalarial drug candidates have been more typically discovered using
phenotypic screening approaches [8–10]. More than seven million compounds have now been
tested against asexual blood-stage parasites. To identify inhibitors targeting other parasite life496 Trends in Parasitology, June 2021, Vol. 37, No. 6
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OPEN ACCESScycle stages, over 500 000 compounds were recently screened against murine liver-stage para-
sites, resulting in the identification of 681 validated hits effective against hepatic schizonts [target
candidate profile (TCP 4)] at submicromolar concentrations [11] (Box 1). In an independent
screen of 70 000 chemical compounds, 17 were identified having transmission-blocking activity
(TCP 5) [12] (Box 1). Over the past decade, some of these active screening hits have been further
profiled and optimized through rounds of medicinal chemistry aimed at identifying a nontoxic
clinical candidate with an acceptable predicted efficacious oral dose in humans; such candidates
could progress to human clinical trials following preclinical good laboratory practice (GLP) safety
studies.
Examples of drug candidates that originated from phenotypic screens include KAE609
(cipargamin) and KAF156 (ganaplacide). Both are effective against Plasmodium parasites at
nanomolar concentrations [13]. The latter is a novel imidazolopiperazine-based antimalarial
that is pan-active against Plasmodium parasites [13,14]. This compound exerts its function by
inhibiting protein trafficking and causes endoplasmic reticulum (ER) expansion in parasites,
though its specific target is unknown [15]. It has good pharmacokinetic properties and is orally
available [16]. Given its blood-stage antimalarial potency as well as transmission-blocking activity,
KAF156 could play an important role in eliminating malaria. KAF156 is now undergoing Phase IIb
clinical trials (NCT03167242) in combination with lumefantrine.
A limitation of phenotypic screens is that, in the absence of biochemical or cellular target
deconvolution assays, there is no information regarding the mechanism of action. Knowing the
target is important for compound optimization and safety evaluation. First, without knowing
which part of the small molecule interacts with its protein target it can be difficult to predict
which chemical changes will result in improved binding and thus improved efficacy. Second,
ignorance of the biological target can hinder optimization of the chemical series against mammalian
or human orthologs that could, in later stages, preclude development. The amount of chemistry
that has been explored through phenotypic screening in the pursuit of potent 'hits' is so extensive
that finding novel compound libraries to screen is becoming increasingly difficult. Despite these
challenges, as mentioned earlier, numerous successful candidates from phenotypic screens
have been identified and are candidates for further development.
Target-Based Drug Discovery
A more elegant approach to drug discovery is target-based discovery. In this case, a recombinant,
chemically validated target is used in biochemical screening. Rational drug design, wherein chem-
ists predict which changes should be made to the drug candidate to optimize potency based on
the target-compound interaction, is also possible. Computational approaches facilitate visualiza-
tion of the interaction between a compound and its target, thereby guiding the structure–activity
relationship (SAR) (see Glossary). Where it is possible to cocrystallize the enzyme, this allows
structure-based and fragment-based drug discovery approaches.
In addition, target-based screening, even without a structure, greatly facilitates drug discovery.
It allows counter-screens against the human homolog to optimize for selectivity. It also allows
for approaches such as DNA-encoded library (DEL) technology. Here, billions of different
compounds, each attached to a DNA barcode, can be incubated with a target in a single test
tube [17]. The approach requires a small amount of target protein (at µg scale) so that multiple
conditions can be tested at once in an efficient manner, together with functional assays, inhibitors
can be identified and characterized. The work is not dependent on having parasites, which re-
quire substantial effort to culture and maintain. Importantly, it can be extended to biological tar-
gets from Plasmodium species refractory to laboratory in vitro culture. DEL technology hasTrends in Parasitology, June 2021, Vol. 37, No. 6 497
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for inflammatory disease [18], and some derivatives are now in clinical trials [19].
Target-based drug discovery is not entirely new for malaria, and several antimalarial drug candidates
that were identified this way have progressed to human trials, including molecules that target
dihydroorotate dehydrogenase (DHODH) and dihydrofolate reductase (DHFR) [20–22].
However, the critical problem has been the dearth of well-validated antiplasmodial targets.
To address the need for additional targets, in the first several years of its existence MalDA was
focused on the discovery and validation of novel targets (see the review in [23]) that could even-
tually be used in target-based drug discovery. Although functional genomic methods have been
used to identify proteins that are essential to parasite viability, and might be attractive targets for
intervention [24,25], chemical and genetic validation are fundamentally different. Genetic valida-
tion means that the gene encoding the protein target is needed for parasite survival. However,
gene essentiality does not mean that the protein is druggable. To be druggable, the protein target
needs to have a binding site for a small molecule that has potential for oral absorption, and it
needs to be expressed at the right time of the parasite’s life cycle. Furthermore, it needs to be
essential such that even partial inhibition with a small molecule results in inhibition of parasite
growth and ultimately parasite death. Such targets are described as 'chemically validated'
(Box 2). Examples of chemically validated targets are given in Table 1.
IVIEWGA: In Vitro Evolution and Whole-Genome Analysis
A very successful method for identifying chemically validated targets is through in vitro evolution
and whole-genome analysis (IVIEWGA), a reverse-genetic method that takes compounds
with activity in phenotypic screens and then identifies the target. Because it is already known
that treatment with a compound will kill the parasite, it is expected that targets revealed with
this approach will be chemically validated.
The first step of IVIEWGA is to expose blood-stage parasites to sublethal concentrations of a
compound in anticipation that a few parasites will eventually develop resistance via mutations
in the target. As malaria parasites have haploid genomes, for some compounds only a single
mutation in one gene might be needed to acquire resistance. The process may take several
months and is typically a function of the intrinsic mutation rate per base pair, the starting number
of parasites and replication cycles used during the selection process, the number of pathways and
steps to resistance, and the type of gene mutation(s) that confers resistance (e.g., mitochondrialBox 2. Classes of Validated Antimalarial Target
Through the collaborative efforts of MalDA andmany other scientific laboratories, many new targets have been discovered
and validated. Since the drug development process requires numerous steps, many compounds inhibiting genetically and
chemically validated targets still need further evaluation before progressing into lead development. For example, the
resistance potential is an important factor to consider when developing drugs. Structural information is needed for
structure-based and fragment-based drug design; toxicity and druggability are key to the design of drug-like inhibitors.
We propose several validated target (VT) classes based on the criteria below. These criteria could be used as a guideline
for future drug development.
VT1 – Genetically validated target. Gene encoding the target demonstrates essentiality from genetic modification assays.
VT2 – Chemically validated target. Inhibition demonstrated with tool compounds.
VT3 – All of the above criteria plus a known resistance potential. This resistance potential can be determined with known
mutations (gene amplifications) in wild-type parasite populations from in vitro evolution assays.
VT4 – Clinically validated targets. Compounds acting against these targets eliminate symptoms of malaria in humans.
Examples include cytochrome bc1, DHODH, and DHFR (Table 1).
498 Trends in Parasitology, June 2021, Vol. 37, No. 6
Table 1. Select Chemically Validated Drug Targets
Drug target Classa Inhibitors Refs
Dihydroorotate dehydrogenase (DHODH) (PF3D7_0603300) VT4 DMS1; DSM74; DSM265; Genz-669178; Genz-666136;
BRD9185
[20,46,74–78]
Cytochrome b1 (mal_mito_3) VT4 Atovaquone; decoquinate; tetracyclic benzothiazepine;
ML238; BRD6323; ELQ300; GW844520; GSK932121
[79–83]
PfATP4 (PF3D7_1211900) VT4 KAE609; GNF-Pf-4492; PA21A092; SJ733 [84–87]
1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR)
(PF3D7_1477300)
VT4 Fosmidomycin [88]
Dihydrofolate reductase-thymidylate synthetase (DHFR-TS)
(PF3D7_0417200)
VT4 MMV027634, P218, pyrimethamine; cycloguanil [21,27,89–92]
Phosphatidylinositol 4-kinase (PI4K) (PF3D7_0509800) VT4 KDU691; MMV390048; KAI407; BQR695; BRD73842 [46,53,93]
Translation elongation factor2 (eEF2) (PF3D7_1451100) VT3 DDD107498 [94]
Farnesyl/geranylgeranyl diphosphate synthetase (fpps/ggpps)
(PF3D7_1128400)
VT3 MMV019313 [95–99]
N-Myristoyltransferase (NMT) (PF3D7_1412800) VT3 IMP-1002; DDD85646 [100]
Hexose transporter 1 (HT) (PF3D7_0204700) VT3 Compound 3361 [57]
Farnesyltransferase (PF3D7_1147500) VT3 BMS-388891; MMV019066 [27,101,102]
Cytoplasmic prolyl-tRNA synthetase (cPRS) (PF3D7_1213800) VT3 Halofuginone [44,103,104]
Isoleucyl-tRNA synthetase (cIRS) (PF3D7_1332900) VT3 Thiaisoleucine [32]
Plasmepsin X, IX, and V
(PF3D7_0808200, PF3D7_1430200, PF3D7_1323500)
VT3 WM382; WEHI 842 [105,106]
Cytosolic lysyl-tRNA synthetase (PfKRS1) (PF3D7_1350100) VT3 Cladosporin; Compound 5 [64,65]




Proteasome subunit beta-5 (PF3D7_1011400) VT3 Bortezomib; Carfilzomib; Carmaphycin B; WLL-vs [67–69]
Cyclin-dependent-like kinase 3 (CLK3) (PF3D7_1114700) VT3 TCMDC-135051 [108]
Niemann–Pick type C1-related protein (NCR1)
(PF3D7_0107500)
VT3 MMV009108; MMV019662; MMV028038 [38]
Acetyl-CoA synthetase (AcAS) (PF3D7_0627800) VT3 MMV689258; MMV019721; MMV084978 [47,48]
Purine nucleoside phosphorylase (PNP) (PF3D7_0513300) VT3 DADMe-ImmG; [109]
Cleavage and polyadenylation specificity factor subunit3 (CPSF)
(PF3D7_1438500)
VT3 Benzoxaborole AN3661 [110]
aSee Box 2 for the criteria of validated target (VT) classes.
Trends in Parasitology
OPEN ACCESSgenes, such as cytochrome bc1, are present at higher copy in the cell, leading to more chances for
mutation [26]).
Shared Bioinformatic Protocols Improves Efficiency
The next challenge in IVIEWGA is to identify the mutations that emerge during long-term culture.
Due to the difficulties of performing genetic crosses of P. falciparum, whole-genome sequencing
and comparative genomics between wild-type and resistant clones is now widely utilized to
identify resistance-causing genetic changes – single-nucleotide variants (SNVs) and copy
number variations (CNVs). Both the evolved resistant clone and the parent clone are
sequenced to at least ~50× average genome coverage. Depending on the time required to select
a resistant line, sequencingmay reveal many possible allelic changes in an evolved clone [27]. The
number of mutations in drug-pressured parasites can be higher when using P. falciparum lines
with mutations in DNA polymerase δ, which appears to confer an increased mutation rate underTrends in Parasitology, June 2021, Vol. 37, No. 6 499
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OPEN ACCESSdrug pressure [28]. However, mutations that confer resistance have specific characteristics: the
allele fraction is typically 100% for alleles that confer resistance, unless the allelic change is within
a CNV; a resistance-conferring change is generally in the core genome [29,30] and not in one of the
genes associated with antigenic variation or at a chromosome end; the allele is not present in the
parent, and themutation leads to a change in the protein-coding sequence. Furthermore, the allelic
change often maps to a conserved part of the predicted protein, sometimes in a small-molecule
binding site (e.g., an ATP-binding site). Because there may be about three SNVs per evolved line
that satisfy these criteria, multiple independent clones are often examined, thereby providing in-
creased confidence in the identification of causative alleles. CNVs can also be identified. In some
cases, SNVs are found within CNVs [29,31,32]. Standardization of the analysis pipeline and a da-
tabase with sequences of hundreds of evolved clones further allow candidate mutations to be
more readily identified by the MalDA consortium. The majority of the targets in Table 1 were either
discovered or rediscovered using IVIEWGA.
A CRISPR/Cas9 Pipeline
Because mutations may randomly arise during long term-culturing, SNVs discovered in experi-
mental evolution cell lines require validation. One method of genetic validation is to perform an
allelic replacement by the site-specific introduction of a mutant allele into a naïve genetic back-
ground, that is, a parasite clone that was not subjected to drug exposure and in vitro evolution.
Although allelic replacement methods have been used in the past [32], recent developments in
gene editing methodologies are rapidly advancing the abilities of researchers to probe gene
functions in malaria parasites [33–35]. Using clustered regularly interspaced short palindromic
repeats/Cas9 (CRISPR/Cas9), it is possible to target double-strand breaks to specific sequences
using guide (g)RNAs to introduce desired SNVs with the aid of short (~500 nt) donor-repair
sequences. This approach is also valuable for dissecting more complex situations in which
multiple mutations may contribute to the observed resistance phenotype.
The next task is to determine whether the resistance-conferring mutation is in the actual target or
in a more general resistance gene, such as pfmdr1. For further target validation, a tunable trans-
lational repression system has been particularly helpful [36,37]. Additionally, dose–response
curves of conditionally expressed proteins (cKD) for compounds that putatively interact with a
specified target protein can be determined at various protein expression levels to determine
whether hypersensitization occurs (as evidenced by a decrease in EC50). Target validation can
be particularly convincing if the phenotype of inhibition by compound aligns with the phenotype
of the knockdown as described in [38–40]. Use of this cKD approach in validating a variety of
putative targets allows for a standardized method to compare the druggability of targets. This
conditional expression system can be used more generally to identify structurally different
compounds engaging the same target, as the effects of SNVs on EC50 will depend on whether
scaffolds share the same target binding or interacting sites.
Examples: In Vitro Evolution Has Proven to Be a Successful Approach for Target Discovery by the
MalDA Consortium
PfNCR1
Very recently, an uncharacterized parasite protein, P. falciparum Niemann–Pick type C1-related
protein (PfNCR1), was first identified by selecting parasites against three diverse antimalarial
compounds using IVIEWGA [38]. PfNCR1 acquired SNVs or CNVs after selections using these
three compounds. Further investigation showed that PfNCR1 localizes to the parasite plasma
membrane and is required for digestive vacuole biogenesis [38]. The essentiality of this gene in
parasite asexual growth, as well as its other druggable features, highlight the possibility that
PfNCR1 could be a novel drug target.500 Trends in Parasitology, June 2021, Vol. 37, No. 6
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Aminoacyl-tRNA synthetases (aaRSs) play a crucial role in protein biosynthesis pathways.
Plasmodium parasites have 36 aaRS enzymes, and given their important functions, targeting
Plasmodium aaRSs provides a new resource of targets for antimalarial drug development. So
far, many Pf-aaRSs have been characterized, such as the arginyl- [41], tryptophanyl- [42,43],
isoleucyl- [32], prolyl- [44], and tyrosyl- [45] aaRSs. These studies provide a basis for future inhibitor
design and screening strategies. A pan-active bicyclic azetidine, BRD3444, was identified from
phenotypic screening [46]. In vitro evolution using BRD1095, a derivate of BRD3444 with
enhanced solubility, identified SNVs in the phenylalanyl-tRNA synthetase (PfPheRS) [46]. Follow-
up in vitro enzyme activity assays confirmed that PfPheRS is the target of bicyclic azetidines.
Acetyl-CoA Synthetase
Acetyl-CoA is a key molecule in cellular metabolism and regulation of cellular acetyl-CoA levels
and is essential for cell survival. Acetyl-CoA is required for the tricarboxylic acid (TCA) cycle,
lipid and phospholipid synthesis, and for histone acetylation, a key regulatory mechanism for
gene expression. IVIEWGA identified point mutations in the P. falciparum acetyl-CoA synthetase
gene, implicating this enzyme as a putative drug target, and metabolomic profiling pointed to
changes in parasite acetyl-CoA levels following drug exposure [47,48]. Subsequent allelic
replacement using CRISPR/Cas9 technology, conditional expression modulation, and enzymatic
analysis of heterologous expressed protein confirm that acetyl-CoA synthetase is the target of
these molecules and that this enzyme is essential for parasite survival [48]. Drugs developed
targeting acetyl-CoA synthetase would have dual action in both the liver and blood stages of
infection and thus be useful in both prevention and treatment.
Other Approaches to Target Identification
For compounds where resistance cannot be achieved, or that are associated with mutations in
general drug-resistance genes rather than their cellular targets, it can be difficult to identify targets
using IVIEWGA alone. As such, other approaches are employed to elucidate their targets or
pathways.
Metabolomic Profiling
Metabolomic profiling measures changes in the parasite’s metabolites after compound exposure
and in some cases can generate a recognizable 'fingerprint' resulting from perturbations in
specific metabolic pathways [27,49,50]. Compounds that act against pyrimidine biosynthesis in
the parasite mitochondrion typically have a distinct metabolic profile, and metabolic profiling
was used to correctly predict themode of action (MOA) of compounds with liver-stage activity
[11]. A recent study led by MalDA collaborators generated metabolic fingerprints or
MetaPrints at different asexual stages of P. falciparum following compound treatments [50].
Metabolomic profiling, combined with stage-specific assays, may also provide insights into the
mode of action of a wide array of antimalarial molecules [51,52]. This approach works best
when comparative MetaPrints for reference inhibitors with similar mechanism of action are avail-
able (e.g., with atovaquone, an inhibitor of pyrimidine biosynthesis).
Chemoproteomics
Chemical proteomics approaches provide alternative routes to identify the molecular target(s) of
phenotypically active compounds. Importantly, these approaches often provide direct evidence
of on-target engagement not provided by the other methodologies employed by the consortium.
One such strategy is to immobilize active compounds onto magnetic beads, with these drug
beads then being used to pull-down interacting proteins from parasite cell extracts. The discrim-
ination of proteins that bind specifically/nonspecifically to beads is improved by carrying out theseTrends in Parasitology, June 2021, Vol. 37, No. 6 501
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specifically to drug beads can then be identified and quantified via mass spectrometry (MS) and
identified as putative drug targets. Indeed, such an approach was used successfully to confirm
that 2-aminopyrazine MMV390048 and its analogs specifically target phosphatidylinositol 4-kinase
(PI4K) in P. falciparum [53]. Although PI4K was also discovered by IVIEWGA with the same
compound, in these elegant studies chemoproteomics was also used to interrogate and rule out
potential 'off-target' human cell interactions that may represent a toxic liability for the development
of this promising antimalarial series. Another successful example using chemoproteomics is the
identification of P. falciparum cGMP-dependent protein kinase (PfPKG) as the primary target of a
pan-active trisubstituted imidazole, MMV030084 [40]. IVIEWGA yielded mutations in tyrosine
kinase-like protein 3 (TKL3), a resistance mediator for PKG inhibitors (e.g., MMV030084), but no
mutations in PfPKG. Combined metabolomics, phosphoproteomics, chemoproteomics, and
genetics identified and confirmed PKG as the target of MMV030084 [40].
In cases where immobilization of compounds onto beads compromises the ability of the com-
pound to bind to its target, or if there is limited or no SAR data available, then label-free proteomic
approaches, such as cellular thermal-shift assay (CETSA) or thermal proteomic profiling (TPP)
can be utilized. Both methods are based on the principle that the binding of a drug to its protein
target can significantly increase the thermal stability of that protein. The thermal stability of proteins
within a parasite cell lysate can be monitored in the presence or absence of the test compound
using quantitative MS enabled by tandemmass tags (TMTs). This approach has recently been ap-
plied to interrogate the target of quinine [54]. Dziekan and colleagues exposedP. falciparum lysates
to different quinine concentrations at 51°C to achieve high proteome coverage [54]. Quantitative
MS provided evidence that P. falciparum purine nucleoside phosphorylase (PfPNP) binds to qui-
nine and is stabilized at 100 nMquinine concentration. Interaction of quinine andPfPNPwas further
supported by crystallography [54]. In common with other chemical proteomics strategies, TPP can
be used to provide direct evidence of on-target engagement and can be used at multiple stages of
the drug discovery process. Chemoproteomics is being employed to identify the molecular targets
of a number of compounds of interest to the MalDA. However, just because a protein is stabilized
by a compound, or interacts with a protein based on crystallography studies, does not mean that
the protein is the compound’s true or only target.
In Silico Approaches
In some cases, targets can be discovered via chemoinformatics. Various phenotypic screening
campaigns have identified more than 30 000 compounds with antimalarial activities [11,55]. If a
compound under consideration shows structural similarity to compounds with known targets,
then specific hypotheses about function can result. MalDA researchers have applied cluster anal-
ysis to successfully identify scaffold families from the Tres Cantos antimalarial set (TCAMS), the
Charles River library, or other compound collections [9,11]. Follow-up drug activity assays
validated the results from the clustering analysis. Additionally, scaffold analysis revealed novel
antimalarial molecules with dual-stage activity, as shown using the chemically diverse Global
Health Chemical Diversity Library [55].
In silico approaches allow researchers to not only predict a specific drug–target interaction but
also provide the opportunity to predict the biological impact of a compound. To achieve this,
chemoinformatic pipelines have been developed. As an example, the open-source MAIP system
[56] illustrates the use of machine learning to predict compounds with possible antimalarial
properties. It is noteworthy to mention that, while these tools provide guidelines for drug-target
identification or parasitological efficacy, follow-up validation is crucial. In silicomethods nonethe-
less reduce experimentation time, resources, and efforts.502 Trends in Parasitology, June 2021, Vol. 37, No. 6
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Evidence of genetic essentiality and a hypothesis can also lead to the prioritization of targets.
For example, P. falciparum blood-stage parasites require host glucose for energy, and the
P. falciparum hexose transporter 1 (PfHT1) can transport both glucose and fructose whereas
host glucose transporter 1 (GLUT1) is selective for glucose. Recent availability of the PfHT1
crystal structure enabled observation that C3361 binding induces conformational rearrangement
of PfHT1, and C3361 derivatives with improved selectivity for PfHT1 over human GLUT1 were
described [57,58]. Together, these findings make PfHT1 an attractive antimalarial target with
the promise of using target-based, structure-guided approaches to develop selective inhibitors
of Plasmodium glucose transport.
Irresistible and Target-less Compounds
Even though in vitro evolution often yields resistant parasites, these attempts can fail. Compounds
with this outcome have been termed 'irresistible' [59]. Irresistible compounds are attractive
starting points for drug development as they are less likely to result in clinical resistance and therefore
remain efficacious for a long time. There are many factors that could potentially contribute to drug
resistance, such as copy numbers of a target, ways to generate resistance, and parasite fitness.
However, to our knowledge, no studies have been performed systematically to compare different
resistance factors. To help predict resistance liability, resistance potential can be quantified as the
minimum inoculum for resistance (MIR) [60] and, in turn, inform drug development prioritization.
In some cases, resistant parasites can be obtained through in vitro evolution experiments;
however, the targets cannot be elucidated. We categorize compounds that only yield mutations
in multidrug-resistance genes (MDR genes, such as pfmdr1 or pfcrt), as target-less
compounds if this is the only information available. P. falciparum parasites acquire CNVs and
SNVs in MDR genes frequently after challenge with different compounds. For example, Cowell
et al. showed that pfmdr1 mutations arose for six of 37 different compounds [27]. Other genes
that were seen frequently included pfcrt and pfaat1 [27].
KAF156 is one such target-less compound. IVIEWGA of the imidazolopiperazine KAF156
showed SNVs in pfcarl; however, mutations in this essential gene also lead to increased EC50
to compounds that are structurally unrelated to KAF156, suggesting that this protein, most likely,
mediates resistance to KAF156 as well as other diverse scaffolds [61–63]. Additionally, 4- and
8-animoquinolines, the arylamino alcohols, and artemisinins may also be considered target-
less. A combination of approaches can be applied to identify targets for compounds for which
using a single strategy proved insufficient [15].
Next Steps: Structure Determination and Progression through the Drug
Discovery Process
Once a target has been identified and validated, concerted efforts are made to determine the struc-
ture (if unknown) as well as produce recombinant protein for target-based screening. Structure deter-
mination is largely performed by MalDA consortium members, the Structure-guided Drug Discovery
Coalitionii, and the Structural Genomics Consortium (SGC)iii, but may also be undertaken by individual
laboratories. Following triaging and validation of hits from the aforementioned target-based screening,
multiple chemical series can be progressed through the drug discovery process, underpinned by
medicinal chemistry integrated with preclinical pharmacology, to deliver quality novel leads whose
characteristics are defined by the MMV Target Candidate Profile (TCP; Box 1) criteria for early leads.
P. falciparum cytosolic lysyl-tRNA (PfKRS1) is a good example of how targets can advance.
PfKRS1was identified as the target of cladosporin using a variety of target deconvolution methodsTrends in Parasitology, June 2021, Vol. 37, No. 6 503
Outstanding Questions
Have phenotypic screening approaches
reached target saturation, and are
new screening methods and chemical
matter needed to find new targets?
Should more natural product libraries
be screened?
Are there any host genes that can
be safely targeted? Can traditional
screening technologies uncover
compounds targeting host determinants
of parasite survival?
Will thermal shift proteomic methods
live up to their promise or do they
work better for identifying the same
cytoplasmic targets that are readily
identified using in vitro evolution?
Can structure-guided drug discovery
and artificial intelligence (AI) deliver
better leads and more potent drug
candidates? Will such delivery be
cheaper and quicker?
Is the emergence of drug resistance
driven by the chemical scaffold or the
target? For example, resistance to
pyrimethamine is due to mutations in
its target, PfDHFR. To overcome this,
compound P218 was identified and
optimized to bind flexibly into the
PfDHFR active site such that P218
showed good antimalarial activity
against both the DHFR mutant and
wild-type P. falciparum parasites, thus
it could potentially be a replacement
for pyrimethamine. Can resistance be
predicted and circumvented?
Can clues about a compound’s
intracellular site of action be obtained
by analyzing the patterns of resistance
mutations (e.g., mutations in proteins
located at the food vacuole, mitochon-
dria, cytosol, etc.)?
How do we find targets for liver stages
or transmission-blocking drugs?
Trends in Parasitology
OPEN ACCESS[64]. Even though cladosporin inhibits PfKRS1 and shows potent activity against Pf3D7 para-
sites (with EC50 = 73 nM), cladosporin cannot be developed as an antimalarial drug due to
its metabolic instability. Nevertheless, PfKRS1, an aaRS (see earlier), is essential in different
parasite life cycle stages and can be selectively inhibited (some compounds show >100-fold
lower activity against the human enzyme, making it an attractive target [64]). To identify novel
PfKRS1 inhibitors and overcome cladosporin liabilities, a crystal structure was determined
and the recombinant protein used to screen ~13 000 compounds [65]. A promising hit was iden-
tified and structure-guided medicinal chemistry efforts resulted in a lead compound with improved
stability [65]. The lead shows excellent oral bioavailability, and reduced parasitemia by 90% in a
severe combined immunodeficiency (SCID) mouse model of P. falciparum infection [65].
The proteasome plays an important role in degrading ubiquitinated proteins to maintain cellular
protein homeostasis [66], and the 20S proteasome is the active core for protein degradation.
The proteasome has been an attractive antimalarial drug target due to its involvement in maintain-
ing proteostasis across the whole life cycle. Many proteasome inhibitors have demonstrated good
activity against malaria parasites; however, as the proteasome is conserved across eukaryotes,
these inhibitors can be toxic to human cells [67]. MS and substrate profiling have been performed
to identify proteasome active site preferences in order to improve inhibitor specificities against
malaria parasites [68,69]. As a result, the highly selective vinyl sulfones, WLW-vs and WLL-vs,
were synthesized [68]. In vitro studies showed that these inhibitors synergized with artemisinin to
enhance clearance of artemisinin-resistant parasites including in mousemodels of malaria infection
[68,70]. The crystal structure of the Pf20S core proteasome with its regulatory PfPA28 cap is now
available and this will provide more structure–function insights into the proteasome that should fa-
cilitate improved inhibitor designs [71].
Concluding Remarks
The MalDA consortium provides an excellent model for collaboration in drug discovery, especially
for rare or neglected diseases. The tuberculosis (TB) Drug Accelerator Program (TBDA) is another
successful collaboration among academic and industry laboratories to speed up the discovery
and development of novel compounds active against TB [72]. In both cases, drug development
may be constrained by limited resources, expertise, and funding. Cooperation can also lessen the
waste of precious resources and knowledge.
MalDA provides a unique forum to accelerate malaria target-based drug discovery. By sharing
resources and expertise among academic and industry partnerships – for example, compounds
that have been selected by MalDA members for further investigation are not only from MMV
libraries but also from outside collaborators – so far, more than 200 compounds are under inves-
tigation for target identification, and at least 23 putative targets have been identified by the MalDA
consortium. Even though questions and obstacles still exist for malaria drug discovery (see
Outstanding Questions), MalDA has built on the advances of parasite biology and has the ability
to validate, express, and screen new malaria targets, resulting in a complementary hit and lead
generation paradigm to deliver into the MMV Discovery portfolio.
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